Lixisenatide, a novel GLP‐1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Recent advances in therapies for the treatment of type 2 diabetes mellitus (T2DM) have led to the development of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), which, unlike insulin and sulphonylurea, are effective, with a low risk of hypoglycaemia. Lixisenatide is recommended as a once‐daily GLP‐1 RA for the treatment of T2DM. In persons with T2DM, lixisenatide 20 µg once‐daily given by bolus subcutaneous injection improves insulin secretion and suppresses glucagon secretion in a glucose‐dependent manner. Compared with the longer‐acting GLP‐1 RA liraglutide, lixisenatide achieved a significantly greater reduction in postprandial plasma glucose (PPG) during a standardized test breakfast in persons with T2DM otherwise insufficiently controlled on metformin alone. This is primarily due to the greater inhibition of gastric motility by lixisenatide compared with liraglutide. The efficacy and safety of lixisenatide was evaluated across a spectrum of T2DM in a series of phase III, randomized, placebo‐controlled trials known as the GetGoal programme. Lixisenatide monotherapy or as add‐on to oral antidiabetic agents or basal insulin achieved significant reductions in glycated haemoglobin, PPG and fasting plasma glucose, with either weight loss or no weight gain. The most frequent adverse events were gastrointestinal and transient in nature. Lixisenatide provides an easy, once‐daily, single‐dose, add‐on treatment to oral antidiabetic agents or basal insulin for the management of T2DM, with little or no increased risk of hypoglycaemia and a potential beneficial effect on body weight.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 3×
“Theoretically, the shorter-acting GLP-1 RAs by virtue of their superior postprandial glycaemic control [30,38], compared with GLP-1 RAs with a prolonged duration of action (with predominant effect in the fasting, non-prandial), should be more effective in combination with basal insulin.”
BackgroundGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Nauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., Hüfner, M., & Schmiegel, W. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8355 · Cited by 605 · cited 1×
“In contrast to other secretagogues, including sulphonylurea and meglitinide hypoglycaemic agents, native GLP-1 and GLP1 mimetics enhance insulin secretion in a glucose-dependent manner [18] and therefore have a low propensity to cause hypoglycaemia.”
ResultAgersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510 · cited 1×
“Liraglutide has a half-life of approximately 11–15 h in healthy individuals [34,35] and is advocated for once-daily administration at any time of the day, independent of meal times.”
BackgroundBuse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506
Willms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502
Research works printed but not linked: 36
- 10.2337/dc12-0413 · DOI · Paper page
- 10.1111/j.1463-1326.2008.00881.x · DOI · Paper page
- 10.1210/jc.85.10.3575 · DOI · Paper page
- 10.1210/endo.134.5.8156917 · doi:10.1210/endo.134.5.8156917 · Paper page
- 10.1111/j.1463-1326.2012.01560.x · DOI · Paper page
- 10.1152/ajpendo.00545.2003 · DOI · Paper page
- Komatsu R, 1989, Glucagonostatic and insulinotropic action of glucagonlike peptide I‐(7–36)‐amide, Diabetes, 38, 902, 10.2337/diab.38.7.902 · DOI · Paper page
- 10.1210/jc.81.1.327 · DOI · Paper page
- 10.1093/ajcn/68.3.525 · DOI · Paper page
- 10.1002/dmrr.1202 · DOI · Paper page
- 10.1016/S1262-3636(08)73398-6 · DOI · Paper page
- 10.1152/physrev.00034.2006 · DOI · Paper page
- 10.2165/00126839-200708030-00002 · DOI
- 10.1016/j.numecd.2008.08.002 · DOI
- 10.5414/CP201462 · DOI · Paper page
- 10.2337/dc10-1393 · DOI · Paper page
- American Diabetes Association, 2012, Introduction: the American Diabetes Association's (ADA) evidence‐based practice guidelines, standards, and related recommendations and documents for diabetes care, Diabetes Care, 35, S1
- 10.1016/S0021-9258(19)36565-2 · DOI · Paper page
- 10.1016/j.beem.2009.03.008 · DOI
- 10.1111/j.1463-1326.2012.01557.x · DOI · Paper page
- 10.2337/dc12-2462 · DOI · Paper page
- 10.1111/j.1463-1326.2012.01618.x · DOI · Paper page
- 10.2337/dc09-2191 · DOI · Paper page
- 10.4158/EP.13.5.444 · DOI
- 10.1055/s-2008-1042426 · DOI · Paper page
- Ratner R, 2011, Efficacy and safety of lixisenatide once daily versus placebo in patients with T2DM insufficiently controlled on sulfonylurea±metformin (GetGoal‐S) [Abstract], Diabetologia, 54, A785
- 10.1016/j.regpep.2013.04.001 · DOI · Paper page
- Becker R, 2012, Augmentation of 1st‐phase insulin release with lixisenatide in non‐diabetic subjects (Abstract 1149‐P), Diabetes, 61, A212
- Becker R, 2012, Restitution of glucose disposition with lixisenatide in T2DM subjects (Abstract 1081‐P), Diabetes, 61, A212
- 10.1111/j.1464-5491.2010.03020.x · DOI · Paper page
- 10.1111/dom.12076 · DOI · Paper page
- 10.2337/dc06-2593 · DOI · Paper page
- 10.1111/dom.12121 · DOI · Paper page
- Raccah D, 2012, Efficacy and safety of lixisenatide in elderly (≥65 yr) and very elderly (≥75 yr) patients with type 2 diabetes: an analysis from the GetGoal Phase 3 program (Abstract 972‐P), Diabetes, 61, A212
- 10.2337/dc08-9025 · DOI · Paper page
- 10.1007/BF00265086 · DOI · Paper page
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Incretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93
Tschöp, M., Nogueiras, R., & Ahrén, B. (2023) · Diabetologia · doi:10.1007/s00125-023-05929-0 · Cited by 92
“administration, allowing lixisenatide to be developed as a once-daily injectable [20].”
BackgroundThe effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy
Oezer, K., Kolibabka, M., Gassenhuber, J., Dietrich, N., Fleming, T., Schlotterer, A., Morcos, M., Wohlfart, P., & Hammes, H.-P. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02135-7 · Cited by 22
“This leads to improved blood sugar control in type 2 diabetes [12–15].”
Background
Metadata
- Authors
- Bolli, G. B., & Owens, D. R.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2014-01-20
- Volume
- 16
- Issue
- 7
- Pages
- 588-601
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1978569902
- Cited by
- 36
- References
- 27
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lixisenatide, a novel GLP‐1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1111/dom.12253
- The paper
- Bolli, G. B., & Owens, D. R. (2014). Lixisenatide, a novel GLP‐1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12253
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.